Ruxolitinib, Topical

Other Dermatologicals · Selective inhibitor of Janus-associated tyrosine kinase JAK1 and JAK2

Indications

Topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Topical treatment of nonsegmental vitiligo.

Dosage

Adults and Children =12 yrs: One 60 gm tube/wk or one 100 gm tube/2 wks. Atopic Dermatitis: Apply a thin layer twice daily to affected areas of up to 20% body surface area. Nonsegmental Vitiligo: Apply a thin layer twice daily to affected areas of up to 10% body surface area. <12 yrs: Not recommended.

Adverse Effects

Atopic dermatitis: Nasopharyngitis, diarrhoea, bronchitis, ear infection, increased eosinophil count, urticaria, folliculitis, tonsillitis, and rhinorrhea. Nonsegmental vitiligo: Application site acne/pruritus, nasopharyngitis, headache, UTI, app site erythema, pyrexia.

Risk Factor (Pregnancy/Lactation)

Contraindications: Lactation. Precautions: Regularly monitor patients for infection and manage it promptly. Perform periodic skin examinations during treatment and following treatment as appropriate. Perform CBC monitoring as clinically indicated.

Interactions

Therapeutic biologics, other JAK inhibitors, potent immunosuppressants such as azathioprine or cyclosporine; avoid.

Advice to Patient

Report any signs and symptoms of infection, thrombocytopaenia, anaemia, neutropaenia, cardiovascular problem. Wear protective clothing and use a broad-spectrum sunscreen to reduce exposure to sunlight and UV light. Lactating mothers should avoid nursing babies during treatment and for 4 weeks after the last dose.

Pharmacokinetics

Metabolism: Hepatic. Half-life elimination: Terminal: Approx. 116 hrs. Excretion: Urine (74%). Faeces (22%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.